The Institut Bordet Clinical Haematology Department specialises in determining and treating diseases of the blood.
The Institut Bordet is committed to the treatment of these diseases and to offering patients high-quality, individual treatment.
In addition to the traditional approach to blood diseases, the Institut is also engaged in the development of innovative and complex techniques and therapies.
The Institut’s mission covers three main university fields: clinical, research and teaching.
The multidisciplinary nature of the Department, in both its diagnostic and therapeutic approaches, forms an integral part of all decisions concerning the patient.
The expertise of the Clinical Haematology Department includes the treatment of:
- high and low grade lymphoma
- multiple myeloma and associated conditions (POEMS syndrome, amyloidosis, etc)
- acute and chronic leukaemia
- myelodysplastic syndromes, myeloproliferative syndromes (Vaquez disease, essential thrombocytosis, myelofibrosis).
The Department has at its disposal all the modern technology needed to ensure the highest level of care:
- sterile isolation facilities for neutropenic patients following chemotherapy or after medullary aplasia of other origin
- stem cell transplant treatment
- development of new transplant techniques (non-myeloablative, T-cell depleted, haploidentical)
- cord blood bank for the ULB
- cytapheresis and photopheresis
- cell therapy.
In addition, in order to offer patients the most innovative treatments, the Department is involved in clinical research activities:
- in collaboration with the EORTC, LYSA, IFM and EBMT in the treatment of malignant haemopathies
- in collaboration with the EORTC in relation to associated infectious diseases
National and international approvals
- since 2006: "JACIE" for haematopoietic stem cell transplants in adults and children
- since 2012: Netcord/FACT accreditation for the cord blood bank
- since 2011: AFMPS for the "banking" of haematopoietic stem cells, cord blood and mesenchymatous cells.
The Department’s specific activities include:
- therapeutic photopheresis for Graft Versus Host Disease
- haploidentical transplants
- new cell immunotherapy protocols (TCAR)
- myeloma clinic comprising doctors (haematologist, radiologist, radiotherapist, surgeon, pain specialist) and paramedical staff (psychologist, dietician, nurse coordinator) specialising in the treatment of this disease.
- expertise in chronic lymphoid leukaemia for over 30 years in close collaboration with research laboratories (prognostic factors, microenvironment, new drug activity, etc) and in clinical research (clinical studies, access to new drugs)
- lymphoma: research in close collaboration with the French group LYSA
- acute leukaemia and myelodysplastic syndromes: international therapeutic protocols (EORTC, GRAALL, APL, etc)
Our commitment to teaching is at all levels of training: medical students, BioMed BACH3 students, oncology nurses, EHA Master Classes, GPs, doctors undergoing specialised training, paramedics and the general public.
The prognostic value of cognitive function, biomarkers of ageing and clinical factors in elderly patients with malignant haemopathy admitted for chemotherapy (Dominique Bron, MD, PhD)
- Project leader : Dominique Bron
- Collaborations : H. Wildiers, M. Delforge (KUL)
- Funding : Télévie, FNRS, Fonds Yvonne Boël
Head of Department
Prof Dominique Bron - Haematological Medicine (rare lymphoma and chronic lymphoid leukaemia)
Heads of Clinic
- Prof Nathalie Meuleman - Haematological Medicine (multiple myeloma and plasmocytary disorders, autografts)
- Prof Philippe Lewalle - Haematological Medicine (myeloproliferative syndrome, chronic myeloid leukaemia and allogeneic transplants)
- Prof Sebastian Wittnebel - Haematological Medicine (leukaemia, myelodysplasia, new drugs and allogeneic transplants)
- Dr Marie Maerevoet - Haematological Medicine (lymphomas and lymphoproliferative disorders, new drugs, autografts)
- Dr Cécile Springael - Haematological Medicine (T lymphomas and rare lymphomas)
- Dr Phuong Huynh - General practitioner (ability of autologous and allogeneic donors to be collected in stem cells and lymphocytes, haemovigilance)
- Dr Marie Vercruyssen - Haematological Medicine (multiple myeloma and plasmocytic disorders, autografts)
- Dr Chloé Spilleboudt - Haematological Medicine (leukemias, myelodysplasias and allogeneic transplantations)
- Dr Adriano Salaroli - Haematological Medicine (myeloproliferative syndromes, chronic myeloid leukemia, leukemia, myelodysplasia and allogeneic transplantation)
Head Nursing (Tel : +32 (0)2 541 33 55)
- Patrick Crombez
Nursing «coordinator of allografts » (Tel : +32 (0)2 541 33 30)
- Marie-France Jaivenois
Nurses (health care coordinators) (Tel : +32 (0)2 541 73 94)
- Sophie Delaunois
- Zilfi Balci
Cytapheresis unit and Stem Cell Collection (Tel : +32 (0)2 541 32 11)
- Philippe Lewalle - Responsible physician
- Adriano Salaroli - Resident
- Corine Mal - Nurse
- Walter Bellemans - Nurse
- Munteanu Nicoleta - Nurse
- Olivier Mugema - Nurse
Transplantation Coordination (Tel : +32 (0)2 541 32 12)
- Sandra Michiels - Coordinator
- Redouane Rouas - Suppleant
Data Managing Unit
- Anne De Meuter - Head Nurse (Tel : +32 (0)2 541 72 05)
- Dominique De Poorter - Nurse (Tel : +32 (0)2 541 35 98)
- Sabrina Costantini - Administrative (Tel : +32 (0)2 541 37 55)
- Delphine Leva - Administrative (Tel : +32 (0)2 541 33 57)
- Gregory Rios - Nurse (Tel : +32 (0)2 541 36 47)
- Aurélie Timmermans (Tel +32 (0)2 541 72 25)
- Olivier Carabin (Tel +32 (0)2 541 37 26)
- Sabine Ackermans (Administration) - Tel : +32 (0)2 541 37 28
- Jennifer Marinus (Consultation) - Tel : +32 (0)2 541 36 84
- Nancy Martin (Consultation) - Tel : +32 (0)2 541 38 78
Mesenchymal stromal cells and natural killer cells: a complex story of love and hate.
Authors : Najar M, Fayyad-Kazan M, Merimi M, Burny A, Bron D, Fayyad-Kazan H, Meuleman N, Lagneaux L
Year : 2019
Journal : Curr Stem Cell Res Ther
Volume : 14(1)
Pages : 14-21
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Authors : Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F
Year : 2019
Journal : Leukemia
Volume : 33
Pages : 776-780
MiR302c, Sp1, and NFATc2 regulate interleukin-21 expression in human CD4+CD45RO+ T lymphocytes.
Authors : El-Said H, Fayyad-Kazan M, Aoun R, Borghol N, Skafi N, Rouas R, Vanhamme L, Mourtada M, Ezzeddine M, Burny A, Fayyad-Kazan H, Badran B
Year : 2019
Journal : J Cell Physiol
Volume : 234
Pages : 5998-6011
Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.
Authors : Quinten C, Kenis C, Decoster L, Debruyne PR, De Groof I, Focan C, Cornelis F, Verschaeve V, Bachmann C, Bron D, Luce S, Debugne G, Van den Bulck H, Goeminne JC, Baitar A, Geboers K, Petit B, Langenaeken C, Van Rijswijk R, Specenier P, Jerusalem G, Praet JP, Vandenborre K, Lycke M, Flamaing J, Milisen K, Lobelle JP, Wildiers H
Year : 2019
Journal : Qual Life Res
Volume : 28
Pages : 663-676
Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report.
Authors : Nelis S, Azerad MA, Drowart A, Lewalle P, Efira A
Year : 2019
Journal : Rev Med Interne
Volume : 40
Pages : 258-261